Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 23, 2014, 05:01:02 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 643296
  • Total Topics: 48946
  • Online Today: 275
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Pregnancy-limited HIV antiretroviral therapy promotes drug resistance  (Read 846 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
HIV-infected women who take antiretroviral drugs for the first time when they become pregnant and discontinue them after delivery are likely to develop antiretroviral resistance, new research suggests.

"The main determinants of resistance selection during pregnancy were the characteristics of the antiretroviral regimen chosen to prevent mother-to-child transmission," the investigators report in the January 2nd issue of AIDS.

Led by Dr. Ruth E. Tuomala from Harvard Medical School in Boston, the researchers evaluated resistance data from 114 antiretroviral-naive, HIV-infected pregnant women in the U.S. who received pregnancy-limited antiretroviral therapy between 1998 and 2004.

The women were treated with zidovudine and lamivudine; 64% also received nelfinavir and 7% received nevirapine. All had 2- or 6-month postpartum plasma samples with HIV RNA levels > 500 copies/mL.

Using allele-specific PCR, the researchers tested for the M184V mutation, associated with high-level resistance to lamivudine and emtricitabine; K103N, associated with resistance to nevirapine and efavirenz; and D30N, associated with resistance to nelfinavir.

Their tests showed that the postpartum rate of single-class resistance was 63.2%. Rates of dual- and triple-class resistance were 10.5% and 1.7%, respectively.

On multivariate analysis, selection of M184V was significantly associated with exposure to dual versus triple-drug therapy (OR 19.64, p < 0.01), and duration of zidovudine exposure (OR 1.29 per additional month, p = 0.03).

Selection of K103N was linked with nevirapine use (OR 9.75, p = 0.01) and length of exposure to zidovudine plus lamivudine (OR 1.46 per additional month, p = 0.02).

Neither the presence of resistance mutations before antiretroviral therapy, nor the first prenatal CD4+ cell count, nor use of hard drugs or alcohol were associated with postpartum detection of the K103N or M184V mutations.

The researchers suggest that "triple-drug therapy should be the preferred mother-to-child transmission prevention approach to preserve future treatment options for others."

Finally, they add, resistance mutations selected during pregnancy are likely to wane over time, so "performing postpartum genotypic resistance testing within 1 to 2 months after delivery would be highly informative for designing future treatment regimens for women exposed to pregnancy-limited antiretroviral therapy and may be useful in guiding the choice of antiretroviral regimen postpartum."


Source

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.